IXC.AX
Healthcare BiotechnologyInvex Therapeutics Ltd
A$0.11
+0.00 +0.00% today
Price History
Not enough data
Key Stats
Market Cap
8.27M
Avg Volume
22,487
EPS
-A$0.02
52W High
A$0.15
52W Low
A$0.09
Div. Yield
0.0%
Valuation
P/B Ratio
2.12
P/S Ratio
176.55
EV/Revenue
90.78
Margins
Gross Margin 100.0%
Operating Margin (1397.9%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
(79.6%)
Return on Equity
(29.5%)
Return on Assets
(19.6%)
Liquidity & Leverage
Current Ratio
26.48
Quick Ratio
26.48
Total Cash
4.02M
Total Debt
0
About
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
www.invextherapeutics.com